Huma and AstraZeneca have partnered to accelerate innovation for digital-first patient care.

Huma Therapeutics Limited, a global digital health technology company focused on digital-first care and research and development to help people live longer and more fulfilling lives, announced a new collaboration with AstraZeneca to drive digital health innovation. This new partnership between Huma and AstraZeneca demonstrates that both companies aim to improve healthcare outcomes by bridging the gap between patients and doctors through digital healthcare tools.

Huma and AstraZeneca will collaborate to develop companion applications for software as medical devices in a variety of therapeutic areas and accelerate the time-to-market for distributed clinical trials. It builds on Huma’s proven technology and enables digital priority care for over 1.8 million active patient users in over 3,000 hospitals and clinics. In addition, Huma’s solutions are designed to work with clinical workflows, making care more efficient and saving time.

We are delighted that AstraZeneca’s support builds on our decade of experience providing digital-first solutions for healthcare and clinical trials. The combination of pioneering leadership, global reach, deep medical knowledge, and digital innovation will help more people live longer, more fulfilling lives through an award-winning1 platform.”

As 95% of chronic disease management occurs outside the clinical setting, the need for excellence in digital-first management is emphasized. AstraZeneca has invested in the development and clinical validation of the patient-centric AMAZE chronic disease management platform to improve patient care. AstraZeneca used the AMAZE platform to conduct clinical research at leading academic healthcare institutions across the United States to reduce healthcare costs while enhancing patient engagement, communication with healthcare teams, and clinical outcomes. The company already has a solid foundation and early success, so our partnership with Huma will take the company further. It will also help companies adopt SaMD.

Ruud Dobber, Vice President and President of AstraZeneca’s Biopharmaceuticals Business Unit, said, “We are thrilled to be working more closely with Huma on our digital health initiatives. We believe that digitization will expand access to healthcare, advance clinical research, and improve the We believe we can identify the gaps, and this innovative partnership will combine our technology with our research and drug development expertise and apply them to global distributed clinical trials to advance the science of the right patient, the right treatment, at the right time.”